NCT00805389 - Study to Compare the Efficacy of GSK Biologicals' Adjuvants in Combination With the Antigen of the Hepatitis B Vaccine | Biotech Hunter

Enrollment

713

Participants

Timeline

Start Date

December 15, 2008

Primary Completion Date

September 29, 2010

Study Completion Date

July 14, 2011

Conditions

Hepatitis B

Interventions

BIOLOGICAL

Engerix-B™

2 doses intramuscular injections

BIOLOGICAL

Fendrix™

2 doses intramuscular injections

BIOLOGICAL

GSK Biologicals' Hepatitis B vaccines (GSK223192A)

2 doses intramuscular injections 3 different formulations of (GSK223192A), each administered to 1 group

BIOLOGICAL

HBsAg (Booster injection)

Single dose intramuscular injection

Trial Locations (14)

1200

GSK Investigational Site, Brussels

2610

GSK Investigational Site, Wilrijk

7100

GSK Investigational Site, La Louvière

9000

GSK Investigational Site, Ghent

12627

GSK Investigational Site, Berlin

13125

GSK Investigational Site, Berlin

20253

GSK Investigational Site, Hamburg

55131

GSK Investigational Site, Mainz

72074

GSK Investigational Site, Tübingen

80636

GSK Investigational Site, Munich

81241

GSK Investigational Site, Munich

83527

GSK Investigational Site, Haag

93053

GSK Investigational Site, Regensburg

97070

GSK Investigational Site, Würzburg